Zevra Therapeutics shares are trading lower after the company announced the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency adopted a negative opinion regarding the Marketing Authorization Application for arimoclomol for the treatment of Niemann-Pick disease type C.

Zevra Therapeutics To Present Two Posters Featuring Long-Term Real-World Data On MIPLYFFA For Treatment Of Niemann-Pick Disease Type C At SSIEM Annual Symposium

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two

HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target

Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $23.

Zevra Therapeutics shares are trading higher after Citizens raised its price target on the stock from $25 to $28.